SANGAMO THERAPEUTICS, INC. (NASDAQ:SGMO) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition. |
On May10, 2017, Sangamo Therapeutics, Inc. issued a press release
announcing its financial results for the quarter ended March31,
2017. A copy of the press release is attached as Exhibit 99.1 to
this Current Report on Form 8-K.
| Item9.01 | Financial Statements and Exhibits. |
(c)Exhibits. The following material is filed as an exhibit to
this Current Report on Form 8-K:
Exhibit No.
| 99.1 | Press Release dated May10, 2017. |
About SANGAMO THERAPEUTICS, INC. (NASDAQ:SGMO)
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has developed technologies available for gene-based therapies. Its product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Its zinc finger nuclease (ZFN) in vivo genome editing approach is being evaluated in Phase I/II clinical trials to treat hemophilia B and lysosomal storage disorders mucopolysaccharidosis (MPS) I and MPS II. It is also conducting a Phase I/II clinical trial to evaluate its adeno associated virus (AAV) complementary deoxyribonucleic acid (cDNA) human Factor 8 gene therapy approach, SB-525, to treat hemophilia A. It has investigational new drug application for SB-525. It is also developing ZFN-mediated genome editing-based therapies for blood disorders and cancer. SANGAMO THERAPEUTICS, INC. (NASDAQ:SGMO) Recent Trading Information
SANGAMO THERAPEUTICS, INC. (NASDAQ:SGMO) closed its last trading session down -0.05 at 4.35 with 374,201 shares trading hands.
